

Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Krishna Institute of Medical Sciences Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Krishna Institute of Medical Sciences Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2021 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Circular No. CIR/CFD/CMD1/44/2019 dated 29 March 2019 issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.no.	Entity	Relationship
1	Krishna Institute of Medical Sciences Limited	Holding Company
2	Arunodaya Hospitals Private Limited	Subsidiary
3	KIMS Hospital Enterprises Private Limited	Subsidiary
4	Iconkrishi Institute of Medical Sciences Private Limited	Subsidiary
5	Saveera Institute of Medical Sciences Private Limited	Subsidiary
6	KIMS Hospital Kurnool Private Limited	Subsidiary
7	KIMS Hospitals Private Limited	Subsidiary
8	KIMS Swastha Private Limited	Subsidiary
9	KIMS Cuddles Private Limited*	Subsidiary
10	KIMS Hospital (Bhubaneswar) Private Limited	Subsidiary

* the subsidiary has filed necessary closure forms for strike off with RoC on February 9, 2021

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matters

6. The accompanying Statement includes the unaudited interim financial results and other financial information in respect of:
- Four subsidiaries, whose unaudited interim financial results include total revenues of Rs Nil, total net loss after tax of Rs. 0.87 million, total comprehensive loss of Rs. 0.87 million for the quarter ended 30 June 2021, as considered in the Statement which have been reviewed by their respective independent auditors.

The independent auditor's reports on interim financial results of these entities have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiaries is based solely on the report of such auditors and procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors.

7. The Statement includes the results for the corresponding quarter ended 30 June 2020 and for the previous quarter 31 March 2021 as reported in these Unaudited Financial Results have been prepared solely based on the information compiled by the management, and have not been subject to audit or review.

Our conclusion on the Statement is not modified in respect of this matter.

For S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004


Navneet Rai Kabra

per Navneet Rai Kabra

Partner

Membership No.: 102328

UDIN: 21102328AAAAFC4435




Place: Hyderabad

Date: 10 August 2021

Krishna Institute of Medical Sciences Limited
Corporate Identity number : U55101TG1973PLC040558
Registered office : 1-8-31/1, Ministers road, Secunderabad, 500003, Telangana, India
Website: www.kimshospitals.com, Email: cs@kimshospitals.com, Tel: 040 7122 5000

Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2021

		(Rupees in millions)			
S.No.	Particulars	Quarter Ended			Year ended
		30-Jun-21	31-Mar-21	30-Jun-20	31-Mar-21
		(Unaudited)	(Unaudited) Refer note 2	(Unaudited) Refer note 2	(Audited)
1	Income				
	(a) Revenue from operations	4,731.79	3,585.38	2,011.01	13,299.37
	(b) Other income	42.73	41.87	43.69	101.65
	Total Income	4,774.52	3,627.25	2,054.70	13,401.02
2	Expenses				
	(a) Purchase of medical consumables, drugs and surgical instruments	1,193.02	773.54	425.51	2,826.39
	(b) Decrease / (increase) in inventories of medical consumables, drugs and surgical instruments	(69.60)	(0.64)	4.21	62.92
	(c) Employee benefits expense	725.13	564.03	467.04	2,202.09
	(d) Other expenses	1,446.56	1,239.66	757.08	4,499.14
	(e) Finance cost	63.22	74.08	91.38	324.97
	(f) Depreciation and amortisation expense	170.88	166.38	169.42	695.36
	Total Expenses	3,529.21	2,817.05	1,914.64	10,610.87
3	Profit before tax (1-2)	1,245.31	810.20	140.06	2,790.15
4	Tax expense				
	(a) Current tax	338.07	233.37	59.90	778.39
	(b) Deferred tax credit	(13.06)	(10.01)	(9.08)	(33.03)
	(c) Adjustment of tax relating to earlier periods	-	0.63	-	(10.00)
	Total tax expenses	325.01	223.99	50.82	735.36
5	Profit for the period/year (3-4)	920.30	586.21	89.24	2,054.79
	Attributable to:				
	Owners of the Company	891.28	578.02	111.27	2,012.19
	Non-controlling interests	29.25	8.19	(22.27)	42.60
6	Other comprehensive income				
	Items that will not be reclassified subsequently to statement of profit and loss				
	- Re-measurement (loss)/gain on defined benefit plans	(1.47)	9.09	(3.16)	(6.28)
	- Income tax effect	0.38	(2.29)	0.80	1.64
	Other comprehensive income, net of tax	(1.09)	6.80	(2.36)	(4.64)
7	Total comprehensive income for the period/year (5+6)	919.21	593.01	86.88	2,050.15
	Attributable to:				
	Owners of the Company	(1.18)	6.42	(2.32)	(4.98)
	Non-controlling interests	0.10	0.38	(0.04)	0.34
8	Paid up equity share capital (face value of Rs.10 each)				775.93
9	Other Equity				7,861.41
10	Earnings / (Loss) per share (of Rs.10 each) : (not annualised for the quarter ended)				
	(a) Basic (Rs.)	11.48	7.72	1.49	26.87
	(b) Diluted (Rs.)	11.48	7.59	1.48	26.42



Notes:

- 1 In terms of Regulation 33 of the SFBI (Listing Obligations and Disclosure Requirements) 2015, this Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2021 ("Unaudited Consolidated Financial Results") of Krishna Institute of Medical Sciences Limited (the "Holding Company" or the "Company") and its subsidiaries, (the Holding Company and its subsidiaries together referred to as the "Group") has been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 10 August 2021 and have been subject to a limited review by the statutory auditors of the Company. An unqualified report was issued by them thereon.
- 2 The Unaudited Consolidated financial results for the corresponding quarter ended 30 June 2020 and for the preceding quarter ended 31 March 2021, have not been subject to an audit or review by our statutory auditors. However, the management has exercised necessary due diligence to ensure that the Unaudited Consolidated financial results for these periods provide a true and fair view of the Group's affairs.
- 3 The Unaudited Consolidated Financial Results of the Group have been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act 2013, as amended, read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) 2015, as amended (the "Listing requirements").
- 4 The Company has completed Initial Public Offer ("IPO") of 25,995,042 Equity Shares of the face value of Rs. 10/- each at an issue price of Rs. 825/- per Equity Share, comprising offer for sale of 23,560,538 shares by Selling Shareholders and fresh issue of 2,434,504 shares. The Equity Shares of the Company were listed on BSE Limited ("BSE") and National Stock Exchange of India Limited ("NSE") on 28 June 2021. Accordingly, the Unaudited Consolidated Financial Results for the quarter ended 30 June 2021 are drawn up for the first time in accordance with the Listing requirements.
- 5 The utilisation of the net IPO proceeds is summarised below:

Particulars	Objects of the issue as per prospectus *	Utilisation upto 30 June 2021	Unutilised amount as on 30 June 2021
Repayment/pre-payment, in full or part, of certain borrowings availed by our Company and by our Subsidiaries	1,500.00	-	1,500.00
General Corporate Purpose	416.60	-	416.60
Total	1,916.60	-	1,916.60

* net of Offer expenses to the extent applicable to the Fresh Issue.

IPO Proceeds, unutilised as at 30 June 2021, were temporarily invested in monitoring agency account.

- 6 The Code on Social Security, 2020 ('Code') relating to employee benefits during employment and post-employment benefits received Presidential assent in September 2020. The Code has been published in the Gazette of India. However, the date on which the Code will come into effect has not been notified and the final rules/interpretation have not yet been issued. The Group is assessing the impact of the Code and will record any related impact in the period of the Code becomes effective.
- 7 The Group operates in one single reportable business segment - "Medical and Healthcare services".
- 8 The outbreak of COVID-19 in many countries has brought about disruptions to businesses around the world and uncertainty to the global economy. The Group is closely monitoring the impact of the pandemic on all aspects of its business, including how it will impact its employees, vendors and business partners. The Group based on the information available to date, both internal and external, considered the uncertainty relating to the COVID-19 pandemic in assessing its impact. Based on the current estimates, the Group expects to fully recover the carrying amount of assets, and does not foresee any material adverse impact on its operations. As the outbreak continues to evolve, the Group will continue to closely monitor any material changes to future economic condition.
- 9 The above Unaudited Consolidated Financial Results of the Group are available on the Company's website www.kimshospitals.com and also on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com), where the shares of the Company are listed.

For and on behalf of the Board

Krishna Institute of Medical Sciences Limited



[Signature]

Dr. B Bhaskara Rao

Managing Director

DIN: 00008985

Hyderabad
10 August 2021

